$XLO News
Last published 1d ago
- 1d agoXLOXilio Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoXLOXilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswireDosed first patient in Phase 1/2 clinical trial for XTX501, a potential best-in-class PD-1/masked IL-2 bispecific, for patients with metastatic NSCLC, and plan to report initial Phase 1 data in the fourth quarter of 2027
- 1w agoXLOXilio Therapeutics to Present at the Stifel 2026 Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 2w agoXLOXilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLCGlobeNewswireXTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors Anticipate reporting initial Phase 1 data in the fourth quarter of 2027 Plan to present a
- 2mo agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 3mo agoXLOXilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswireReceived FDA clearance of IND application for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Advancing IND-enabling studies for potential first-in-class multi-specific, masked T cell engager programs
- 4mo agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 4mo agoXLOXilio Therapeutics Appoints Ben Harshbarger as Chief Legal OfficerGlobeNewswireWALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 6mo agoXLOXilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswireOn track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a
- 6mo agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer,
- 6mo agoXLOXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2GlobeNewswireXTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models Consistent with Xilio's clinically-validated masking technology, XTX601 was well
- 6mo agoANIKXLOXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsGlobeNewswireWALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 7mo agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 7mo agoXLOXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireXTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class multi-specific,
- 8mo agoXLOXilio Therapeutics Announces 1-for-14 Reverse Stock SplitGlobeNewswireWALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 8mo agoXLOXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with
- 8mo agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 9mo agoXLOXilio Therapeutics Announces Pricing of Underwritten OfferingGlobeNewswireWALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer,
- 10mo agoXLOXilio Therapeutics Highlights Upcoming Milestones and Recent Corporate UpdatesGlobeNewswireReceived $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second
- 12mo agoXLOXilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2025 Financial ResultsGlobeNewswireReported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data
- 1y agoXLOXilio Therapeutics Announces Late-Breaking Phase 2 Data for Vilastobart in Patients with MSS mCRC and High Plasma Tumor Mutational Burden at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewswire40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful
- 1y agoXLOXilio Therapeutics Highlights Portfolio of Differentiated Masked Immunotherapies at Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewswirePreclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio's ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual MeetingGlobeNewswireWALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual MeetingGlobeNewswireWALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with GileadGlobeNewswirePhase 1 data for efarindodekin alfa (XTX301) demonstrate promising anti-tumor activity in patients with advanced solid tumors Achievement of milestone extends anticipated cash runway into first quarter of 2027
- 1y agoXLOXilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial ResultsGlobeNewswireAnnounced updated Phase 2 data at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, demonstrating deep and durable responses and a meaningfully differentiated safety and tolerability profile for an
- 1y agoCPRXXLOCatalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of DirectorsGlobeNewswireCORAL GABLES, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:CPRX) today announced the appointment of Daniel Curran, MD, to its Board of
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of DirectorsGlobeNewswireWALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Closing of $50.0 Million Public OfferingGlobeNewswireTotal gross proceeds of up to $150.0 million before the end of 2026 if all Series B warrants and Series C warrants are exercised for cash Xilio may elect to cancel unexercised Series B or Series C warrants
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Pricing of $50.0 Million Public OfferingGlobeNewswireWALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Proposed Public OfferingGlobeNewswireWALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerGlobeNewswire26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to
- 1y agoXLOXilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial ResultsGlobeNewswireUpdated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC)
- 1y agoXLOXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with
- 1y agoXLOXilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual MeetingGlobeNewswireWALTHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireAdditional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T cell engager programs
- 1y agoXLOXilio Therapeutics to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoXLOXilio Therapeutics Announces Multiple Masked T Cell Engager ProgramsGlobeNewswireAlso entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended anticipated cash
- 1y agoABBVXLOAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesGlobeNewswireCollaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagersXilio to host investor conference call and
- 1y agoABBVXLOAbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated ImmunotherapiesPR NewswireAbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated...
- 1y agoXLOXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
- 1y agoONCYAGENGHXLO+2Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers SymposiumPR NewswireUSA News Group News Commentary – Big developments are expected this week at the 2025 ASCO Gastrointestinal Cancers Symposium, running January 23-25...
- 1y agoXLOXilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal CancerGlobeNewswire27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels of carcinoembryonic
- 1y agoXLOXilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living